Research progress in clinical trials of new drugs and candidate drugs for type 2 diabetes mellitus
10.12092/j.issn.1009-2501.2024.10.012
- VernacularTitle:2型糖尿病新药及候选药物临床试验研究进展
- Author:
Xin ZHOU
1
,
2
;
Zhi WANG
;
Wenyu DU
;
Zihan LIU
;
Ying LI
;
Zhanjun DONG
Author Information
1. 河北医科大学研究生学院,石家庄 050017,河北
2. 河北省人民医院药学部,石家庄 050057,河北
- Keywords:
type 2 diabetes mellitus;
clinical tri-als;
drug targets
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2024;29(10):1185-1193
- CountryChina
- Language:Chinese
-
Abstract:
A number of drugs for the treatment of type 2 diabetes mellitus(T2DM)are currently under clinical investigation,including the sodium-dependent glucose transporters 2(SGLT2)inhibitor rongliflozin,the SGLT1/2 inhibitor LIK066,the di-peptidyl peptidase-4(DPP-4)inhibitor DBPR108,the glucagon-likepeptide-1 receptor(GLP-1R)ago-nist CJC-1134-PC,the G-protein-coupled receptor 40(GRP40)agonist SCO-267 and the Glucokinase(GK)agonist PB201.This article briefly reviews the clinical research progress of drugs targeting the above targets in the field of T2DM treatment,in or-der to provide reference for the treatment of T2DM patients.
